- Report
- May 2024
- 200 Pages
From €3981EUR$4,150USD£3,420GBP
- Report
- April 2023
- 124 Pages
Global
From €4557EUR$4,750USD£3,914GBP
- Report
- November 2021
- 40 Pages
China
From €2494EUR$2,600USD£2,143GBP
- Report
- July 2021
- 50 Pages
China
From €2494EUR$2,600USD£2,143GBP
From €2494EUR$2,600USD£2,143GBP
- Report
- June 2021
- 50 Pages
China
From €2494EUR$2,600USD£2,143GBP
- Report
- May 2021
- 50 Pages
China
From €2494EUR$2,600USD£2,143GBP
- Report
- June 2022
- 114 Pages
Global
From €4792EUR$4,995USD£4,116GBP
- Report
- August 2022
- 120 Pages
Asia Pacific
From €2015EUR$2,100USD£1,731GBP
€2878EUR$3,000USD£2,472GBP
- Report
- March 2020
- 69 Pages
United States
From €2015EUR$2,100USD£1,731GBP
€2878EUR$3,000USD£2,472GBP
- Report
- March 2021
- 94 Pages
Global
€21104EUR$22,000USD£18,130GBP
- Report
- January 2021
- 30 Pages
Global
€1264EUR$1,318USD£1,086GBP
- Report
- June 2019
- 679 Pages
Global
€21104EUR$22,000USD£18,130GBP
- Drug Pipelines
- January 2018
- 19 Pages
Global
From €9593EUR$10,000USD£8,241GBP
- Drug Pipelines
- January 2018
- 9 Pages
Global
From €9593EUR$10,000USD£8,241GBP
- Drug Pipelines
- January 2018
- 16 Pages
Global
From €9593EUR$10,000USD£8,241GBP
- Drug Pipelines
- January 2018
- 21 Pages
Global
From €9593EUR$10,000USD£8,241GBP
- Drug Pipelines
- January 2018
- 9 Pages
Global
From €9593EUR$10,000USD£8,241GBP
- Drug Pipelines
- January 2018
- 13 Pages
Global
From €9593EUR$10,000USD£8,241GBP
- Drug Pipelines
- January 2018
- 16 Pages
Global
From €9593EUR$10,000USD£8,241GBP
The Prostate Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat prostate cancer. Prostate cancer is the most common cancer in men, and the drugs used to treat it can vary depending on the stage and severity of the disease. Common treatments include hormone therapy, chemotherapy, and radiation therapy.
The Prostate Cancer Drugs market is highly competitive, with many companies vying for market share. Major players in the market include Astellas Pharma, Bayer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. These companies are constantly researching and developing new drugs to treat prostate cancer, as well as improving existing treatments. Show Less Read more